Epigenetic therapies demonstrate significant clinical activity in acute myeloid leukemia (AML) and myelodysplasia (MDS) and constitute an important new class of therapeutic agents. However hematological responses are not durable and disease relapse appears inevitable. Experimentally, leukemic stem/progenitor cells (LSC) propagate disease in animal models of AML and it has been postulated that their relative chemo-resistance contributes to disease relapse. We serially measured LSC numbers in patients with high-risk AML and MDS treated with 5'-azacitidine and sodium valproate (VAL-AZA). Fifteen out of seventy-nine patients achieved a complete remission (CR) or complete remission with incomplete blood count recovery (CRi) with VAL-AZA therapy. There was no significant reduction in the size of the LSC-containing population in nonresponders. While the LSC-containing population was substantially reduced in all patients achieving a CR/CRi it was never eradicated and expansion of this population antedated morphological relapse. Similar studies were performed in seven patients with newly diagnosed AML treated with induction chemotherapy. Eradication of the LSC-containing population was observed in three patients all of whom achieved a durable CR in contrast to patients with resistant disease where LSC persistence was observed. LSC quantitation provides a novel biomarker of disease response and relapse in patients with AML treated with epigenetic therapies. New drugs that target this cellular population in vivo are required.
INTRODUCTION
Despite advances in myelosuppressive chemotherapy and allogeneic transplantation the majority of adults with acute myeloid leukemia (AML) and high-risk myelodysplasia (MDS) still die of resistant or relapsed disease. 1 This coupled with the unacceptable toxicity of both treatment modalities in older patients makes the identification of new therapeutic options an urgent necessity. Epigenetic therapies, specifically DNA methyltransferase inhibitors and histone deacetylase inhibitors are important new drugs in the treatment of AML and MDS, particularly in older patients unable to tolerate intensive chemotherapy. [2] [3] [4] [5] [6] [7] However, their utility is limited by the fact that clinical responses are of short duration and disease relapse is almost universally observed.
In AML, a small heterogeneous population of leukemic stem/ progenitor cells (LSC) present at diagnosis can propagate leukemia in vivo and give rise to bulk disease [8] [9] [10] [11] [12] Recently, we further characterized CD34 þ LSC populations (present in most AML patients where functional LSC can be demonstrated) by showing coexistence of two distinct LSC populations with functional leukemia-propagating activity in serial xenotransplant assays. 13 These two populations most closely resemble normal lymphoid-primed multi-potential progenitors (LMPP-like LSC) (Lin-CD34 þ CD38-CD90-CD45RA þ ) and granulocyte-macrophage progenitors (granulocyte-monocyte progenitor fraction (GMP)-like LSC) (CD34 þ CD38 þ CD123 þ /loBAH-1-CD45RA þ ).
On the basis of limited experimental data 14 it has been postulated that human AML LSC populations are relatively chemoresistant compared with bulk blast cells leading to the largely untested hypothesis that drug-resistant LSC form a cellular reservoir, which drives clinical relapse. However, only limited studies have examined the impact of conventional chemotherapy on LSC numbers [15] [16] [17] and none have been performed in patients treated with epigenetic therapies. This is partly explained by the fact that functional LSC populations had not, until recently, been rigorously characterized immunophenotypically. An additional, under-recognised factor contributing to the absence of correlative biological data is the small size of early phase trials of epigenetic therapies, which results in only a very limited number of responding patients being available for correlative LSC studies. As a consequence the biological impact of epigenetic therapies in patients with AML and MDS, and how this might correlate with clinical response remains unknown. We, therefore, serially measured LMPP-like and GMP-like LSC populations, with reference to normal controls in order to provide a highly sensitive measure of changes in stem/progenitor compartments, in a large Phase II study of patients with AML/MDS treated with the DNA methyltransferase inhibitor 5'-azacitidine (AZA) and the histone deacetylase inhibitor sodium valproate (VAL).
PATIENTS AND METHODS

Trial design
Patients 418 years of age with a WHO diagnosis of relapsed/refractory AML or high-risk MDS deemed unfit for intensive chemotherapy were recruited to the VAL-AZA study (Eudract No: 2005-000550-75 ) between 6/2006-3/2010 . Clinical responses were censored at 13/4/2011 (median follow up 226 days; range 16-1374 days). Patients received oral sodium valproate (200 mg total dissolved solids), which was increased by 500 mg every 4 days to maximum tolerated dose, or 3 g and monthly courses of AZA. Three sequential escalating subcutaneous AZA dose cohorts were studied: 50 mg/m2 for 5 days (13 patients); 75 mg/m 2 for 5 days (32 patients); 75 mg/m2 for 7 days (34 patients). Theophylline (175 mg od) and all trans-retinoic acid (ATRA) (45 mg/m 2 od) were administered continuously. Clinical response was assessed at 1, 3 and 6 months and B3 monthly thereafter using Cheson criteria. 18 Complete remission (CR) was defined as neutrophils 41 Â 10 9 /l; platelets 4100 Â 10 9 /l and o5% bone marrow blasts. Complete remission with incomplete blood count recovery (CRi) was defined as o5% bone marrow blasts with incomplete count recovery and partial remission (PR) as X50% reduction in bone marrow blasts. Patients achieving a major clinical response (MCR) (CR, CRi or PR) after 6 cycles continued treatment until response loss. Toxicity was scored by NCI CTCAE criteria (http://ctep.cancer.gov/protocol Development/electronic_applications/ctc.htm).
Statistical analysis
Survival estimates were calculated by Kaplan-Meir and Cox proportional hazard model. 19, 20 Overall survival was calculated from study entry until date of death or censor date (Supplementary Data).
Immunophenotyping studies Quantitation of myeloid progenitors and LSC was performed in bone marrow aspirates from patients treated on the VAL-AZA trial and normal control bone marrow using methodology described in Figure 1a (additional information and details of the three immunophenotyping panels are described in Supplementary Materials and Methods and Supplementary  Figures 1, 3 and 5 ). In summary, we measured the size of the Lin-CD34 þ compartment as a percentage of total-nucleated cells in freshly isolated samples and then, in the CD34 þ enriched samples, determined the size of the stem/progenitor populations as a percentage of the Lin-CD34 þ The mean % of a normal combined LMPP þ GMP population as a % of TNC is also shown. This allows the fold difference in SPC in the patient's sample compared with the normal mean value to be calculated (% of LMPP/GMP of TNC in the patient's sample divided by the mean normal % of LMPP/GMP). (c) The fold difference change in the size of the LMPP/GMP population (as a % of TNC) compared with the mean normal LMPP/GMP population (as a % of TNC), calculated in (b), is depicted on the y axis (solid orange line). The x axis shows when the samples were taken; at diagnosis (D) and before the therapy cycle number indicated. The upper limit of the normal variation in fold difference (ULN) for the LMPP þ GMP progenitor population is indicated by a dashed orange line (1.5 fold-data in Figure 1 ). The blast count at each time point is indicated by the green line. The upper limit of the normal blast count (5%) is illustrated by a dashed green line. The color reproduction of this figure is available on the Leukemia journal online.
compartment. Finally, we expressed the size of the stem/progenitor compartment as a percentage of total-nucleated cells.
Molecular and FISH analysis and colony assays
Detailed protocols for molecular and fluorescence in situ hybridization (FISH) analyses are described in Supplementary Methods. Colony assays were performed and analyzed as described previously. 13 
RESULTS
Patients and toxicity
The demographics of the 79 patients enrolled in the VAL-AZA study are described in Table 1 and their clinical details are described in Supplementary Table 1 . Sixty-four patients had AML and 57 had received prior intensive chemotherapy. Forty-nine patients completed X3 cycles of AZA: 30 patients withdrew from trial therapy before completion of three cycles because of disease progression (11) , drug intolerance (9), concurrent illness (9) or selfwithdrawal (1) . Adverse events are summarized in Supplementary Table 2 . Twenty patients discontinued trial medications because of treatment-related toxicities. The commonest cause of treatment discontinuation was VAL-related fatigue/somnolence (n ¼ 11), highlighting the need to identify histone deacetylase inhibitors with an improved safety profile.
Clinical response and prognostic factors of response A major clinical response (MCR) was observed in 26/79 patients: 15 patients achieving CR/CRi and 11 PR (Table 1 and  Supplementary Table 3 ). The median time to achieve MCR and maximal response was two (range 1-4) and three cycles (range 1-6), respectively. Fifty two percent of patients who received X3 cycles of AZA achieved an MCR. In patients who achieved a CR/CRi the median response duration was 342 days (range 18-1297 days). The median overall survival for the whole population was 7.4 months (95% CI 5.6-12.3). In patients who achieved a CR/CRi the median overall survival was 18.2 months compared with 5 months for patients who failed to respond or only achieved a PR (P ¼ o0.001) (Supplementary Figure 2) contrasting with previous reports in high-risk MDS patients where survival benefit was independent of marrow response (5) . No factors predictive of acquisition of CR or CRi were identified in univariate or multivariate analysis.
The mechanism of action of epigenetic therapies remains unknown. Mutations in DNMT3A, 21,22 IDH1 23 and IDH2 genes 24 may determine methylation state in AML 25 and have been predicted to contribute to clinical response. In patients in whom material was available for analysis, we identified mutations in DNMT3A (10/50), IDH1 R132C (6/51), IDH2 R140Q (6/51) and IDH2 R172K (1/51) (Supplementary Table 1 ). We were unable to demonstrate any correlation between the mutational status of these genes and the likelihood of achieving a MCR.
Immunophenotypic profiles at diagnosis
The immunophenotypic profile at diagnosis of CD34 þ CD38 þ (available in 45 samples) and CD34 þ CD38 À compartments (in 24 cases) in patients treated on the VAL-AZA study mirrored that observed in our previous study 13 supporting the rationale for serially measuring the size of these populations in response to drug treatment (Supplementary Table 4 ).
Persistence of immunophenotypically defined stem/progenitor compartments in patients achieving a CR during VAL-AZA therapy We studied the impact of continuous VAL-AZA therapy on the size of the expanded LMPP-like/GMP-like and multipotent progenitor (MPP)-like/common myeloid progenitor fraction-like compartments, with reference to rigorously defined normal controls, in 37 patients. We first focused on four patients achieving a CR/CRi (patient numbers: 44, 45, 57 and 67) ( Figures 1-4 ) in whom multiple sequential marrow samples were available. Although the percentage of LMPP-like and GMP-like populations was similar to the absolute blast count at presentation, we observed persistent abnormal expansions of immunophenotypically defined leukemic stem/progenitor compartments despite the acquisition of a morphological CR and normalization of blast counts after treatment with VAL-AZA in all four patients. In two patients it was possible, using FISH studies, to confirm that these cells were leukemic in origin.
In patient 44 there was a 141-fold increase in the Lin-CD34 þ CD45RA þ CD123 þ (LMPP þ GMP) compartment at diagnosis at a time when the marrow blast count was 20% (Figures 1b, c) . With treatment there was a reduction in size of the LMPP/GMP compartment but even at the time of acquisition of maximal morphologic response (cycle 3) the LMPP/GMP compartment failed to return to normal remaining 412-fold larger than the normal control. The patient withdrew from active therapy at cycle 22 and relapsed morphologically 30 months after commencing VAL-AZA therapy.
In patient 57 both LMPP-like and GMP-like compartments were expanded (545-fold and 24-fold, respectively) at diagnosis Leukemic stem cell quantitation in AML C Craddock et al ( Figure 2 ). Despite achieving a morphological CR the LMPP population remained abnormally expanded (at least sixfold greater than normal) in three separate samples over the next 6 months. At the time of frank morphologic relapse (month 11), there was a large expansion in both LMPP and GMP populations. This patient illustrates the increased sensitivity provided by monitoring both LMPP and GMP populations as the very small size of the normal LMPP population (0.02% of total-nucleated cells) allowed detection of abnormal expansion in this compartment with great sensitivity. Pathologically expanded LSC populations were also present in patients 45 and 67 despite the acquisition of a morphological remission with VAL-AZA therapy. In both patients, the leukemic origin of the persistent LSC populations was confirmed by FISH technology. In patient 45 (Figures 3 a-b ) the LMPP-like and GMP-like populations were 354-fold and 210 fold expanded at diagnosis. FISH analysis showed 90-100% of fluorescence activated cell sorting-sorted CD34 þ CD38 À and GMP-like populations were leukemic, at a time when the populations were 235 and 55-fold expanded, respectively (Figures 3c and d) . By cycle 3, when the patient was in CR, the LMPP-like and GMP-like populations remained abnormally expanded (65-fold and 15-fold, respectively) and continued to contain karyotypically abnormal cells. Four months later (month 7) significant expansion of both the LMPP-like and GMP-like compartments in the marrow was observed, which antedated morphological relapse by 8 months. Interestingly, at this stage even though the abnormal expansion of the LMPP-like compartment was larger than the GMP-like compartment at presentation, the proportion of leukemic cells detected by FISH was greater in the GMP-like compartment. These observations highlight the possibility of differential sensitivity to VAL-AZA therapy within distinct LSC-containing populations within the same patient.
Patient 67, who underwent an allogeneic transplant in CR after VAL-AZA therapy, is the only patient in the series to achieve a durable remission (Figure 4 ). Both the LMPP-like and GMP-like compartments were abnormally expanded (35-fold and 52-fold, respectively) before the commencement of VAL-AZA therapy. This patient had a reduced intensity unrelated donor transplant, at a time when clonally abnormal cells were detectable in the LSC compartment, and remains in remission 30 months posttransplant. Of interest, although clonally abnormal cells were detectable in the LSC compartment immediately pretransplant, none were detectable at 1 and 6 months post-transplant.
Serial quantitation of the LSC compartment during VAL-AZA treatment in patients failing to achieve a CR Only minimal changes were observed in the size of the pathologically expanded LSC-containing populations in the 19 patients who either failed to respond or only achieved a PR after VAL-AZA therapy (Supplementary Figure 4) . In patients where LSC-containing populations co-exist in LMPP and GMP compartments, such as patients 49 and 63, differential sensitivity to VAL-AZA was again demonstrated by marked differences in the degree of cytoreduction achieved with continuous therapy (Supplementary Figure 4B) . Leukemic stem cell quantitation in AML C Craddock et al remission, we studied the impact of VAL-AZA treatment on in vitro myeloid colony output in both responding and non-responding patients. Restoration of normal colony output was only observed in patients who achieved a CR/CRi after VAL-AZA treatment (n ¼ 3) and no improvement in colony production was seen in patients who failed to respond or only achieved a PR (n ¼ 11) (Supplementary Tables 5 and 6 ). Thus, the persistence of expanded LSC-containing populations does not appear to hinder normal in vitro myeloid colony formation. Myeloid colony output remained severely impaired in patients who achieved only a PR (despite a 450% reduction in blast numbers) consistent with the observation that clinical benefit in terms of improved survival is only observed in patients achieving a CR/CRi. These data identify restoration of normal colony output as a potentially useful surrogate marker of response requiring further examination in future clinical trials of epigenetic therapies.
Impact of induction chemotherapy on LSC compartment in patients with newly diagnosed AML We next compared the changes in the size of the LSC compartment produced by myelosuppressive chemotherapy with those observed before treatment with epigenetic drugs. In contrast to the impact of VAL-AZA therapy, LSC-containing LMPPand GMP-like populations returned to within normal limits after one or two courses of induction chemotherapy in three newly diagnosed patients with AML. Each of these patients (numbers 1270, 1338 
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Bone marrow (BM) blast counts were also available pre-cycle 7 (0%), pre-cycle 12 (0%). Peripheral blood blast counts were avilable at months 30 and 34 (shown by an asterisk). and 1499) remains in remission at 8-14 months from diagnosis ( Figure 5 ). In contrast, the LMPP and GMP-like populations failed to normalize in four patients, two of whom had refractory disease and two of whom relapsed after achieving a morphological CR. Of interest, all these patients had NPM1 mutations and a low number of CD34 þ blasts (as a percentage of total-nucleated cells), in contrast to the VAL-AZA patients. Consequently, the size of the LMPP-like and GMP-like populations (which are CD34 þ ) are much lower than the blast count.
Comparison of different methods of quantitating immunophenotypic stem/progenitor populations Previous studies in AML of the response of putative malignant stem/progenitor populations to treatment have been restricted to patients receiving myelosuppressive chemotherapy and have only monitored the CD34 þ CD38-compartment. 15, 17, 26 We, therefore, wished to compare the results of an LSC-tracking strategy based on sequential quantitation of a rigorously defined LMPP-like/GMPlike leukemic stem/progenitor population, with reference to normal controls, with an approach utilizing serial measurement of the bulk CD34 þ CD38 À compartment (Supplementary Figure 6) . Although reductions in the size of the CD34 þ CD38 À population, produced by either VAL-AZA treatment or myelosuppressive chemotherapy, broadly tracked those observed in the LMPP-like and GMP-like stem/progenitor population there were two important clinical settings in which the latter methodology appeared to be more sensitive. Firstly, at presentation the expansion of the CD34 þ CD38 À population was smaller than that of the LMPP-like population, thus potentially under-estimating the size of the LSC compartment. Furthermore, while treatment resulted in normalization in the size of the CD34 þ CD38 À population, a residual population was observed to persist in the LMPP-like population in two of three VAL-AZA patients who achieved a CR.
DISCUSSION
This is the first study to measure the impact of epigenetic therapies on LSC-containing populations in patients with AML/ MDS and demonstrates that although these agents reduce the size of LSC-containing compartments, they fail to eradicate this population, even in patients in morphologic remission. Our data address a number of issues relevant to optimization of epigenetic therapies in myeloid malignancies. The failure of VAL-AZA therapy to eradicate residual LSC-containing populations provides a plausible biological explanation for the apparent inevitability of disease relapse observed using these agents. The scheduling of DNA methyltransferase inhibitors and histone deacetylase inhibitors administration, as well as new drugs in both classes, must, therefore, be studied with the aim of more effectively targeting the LSC compartment. Quantitation of LSC-containing populations should be incorporated into such studies as a key biological end point. Alternative, potentially adjunctive, strategies to target this reservoir of cells could include low-dose chemotherapy combinations or immunotherapeutic strategies such as reduced intensity allogeneic transplantation or tumor antigen vaccination. The observation that restoration of normal myeloid colony output and reduction in the size of the immunophenotypic stem/ progenitor cell compartment was restricted to patients who achieved a CR/CRi, and was not seen in patients who only achieved a PR, is consistent with the survival benefit of VAL-AZA treatment being restricted to patients who achieved a CR/CRi. Furthermore, it identifies reduction in the size of the LSC compartment as a potentially important biomarker of clinical response in patients with AML treated with epigenetic therapies, which should be validated in future clinical trials. Our data contrast with previous studies of AZA monotherapy in patients with high-risk MDS patients where improved survival was seen regardless of marrow response 5 and suggests the possibility of a different mechanism of action of epigenetic therapies in AML and MDS.
In this study we observed expansion of the persistent LSCcontaining population before relapse in patients who had achieved a morphological remission with VAL-AZA therapy. In this context, it is noteworthy that the only patient in whom residual clonogenic stem/progenitor cells were eradicated was the patient who received an allograft. The optimal timing of allogeneic transplantation in patients who have achieved a morphological remission with epigenetic therapies is an increasingly common therapeutic challenge given the inevitability of disease relapse without transplantation, but the substantial toxicity of allografting. Currently there are no reliable predictors of the timing of disease relapse in patients treated with epigenetic therapies, and further studies incorporating LSC quantitation in patients who have achieved a CR are now required to confirm the utility of monitoring this compartment as a predictor of disease relapse.
In contrast to the persistence of the LSC compartment observed in patients treated with epigenetic therapies, conventional chemotherapy appeared to have the capacity to normalize this population in newly diagnosed AML patients. Of interest, normalization of the LSC compartment by intensive chemotherapy was associated, in this small series, with freedom from disease relapse in contrast to patients in whom LSCs were observed to persist. These observations now require validation in a larger cohort of patients treated with myelosuppressive chemotherapy. The methodology we describe for LSC tracking has potential advantages compared with previously described approaches. 15, 17, 26 First, we monitored both CD34 þ CD38 À and CD34 þ CD38 þ compartments, unlike previous studies, which focused on quantitation of CD34 þ CD38 À cells alone. Second, our immunophenotyping strategy did not rely on expression of aberrant cell-surface markers on LSCs 15 or markers expressed on LSCs in some, but not all, patients, 26 but measured instead defined LSC-containing populations. In addition our methodology does not require additional staining steps, 17 which increases its applicability to routine clinical practice. Finally, by combining our strategy with fluorescence activated cell sorting-sorting and clonal analysis we are able to obtain categorical evidence of LSC persistence in patients treated with epigenetic therapies, as well as insights into clonal variation within different LSC-containing populations in response to treatment.
Taken together these correlative biological studies demonstrate the persistence of leukemic stem/progenitor cells in patients treated with epigenetic therapies and identify serial quantitation of this population both as a potentially important biomarker of clinical response and relapse, and a guide to the design of novel therapeutic strategies in adult AML.
